|Antibody Name:||Fd79 (IgG SGIIIB | k SGIII)|
Co, M.S., Deschamps, M., Whitley, R.J. and Queen, C.
"Humanized antibodies for antiviral therapy."
Proc. Natl. Acad. Sci. USA (1991) 88: 2869-2873.
(See also mAb Fd138-80 in this reference).
|Acceptor Antibody:||Human IgG1 | k|
|Antigen:||Herpes simplex virus (HSV) gB glycoprotein|
|Laboratory:||Protein Design Labs, CA; Univ. Alabama, AL|
|Design:||As for Anti-Tac.|
VH human POM | VL human POM
Heavy and light chains from the same human antibody "to reduce the possibility of incompatibility in the assembly of the two chains".
|CDRs:||All 6 from VH and VL, Kabat Definition.|
VH A93L | VL Y49K since they showed contacts with the CDRs in the model.
VH L81Q Y103W | VL V9A S41G G42Q S77R (!mouse residue is P!) Q79E consensus human residues (identical to Fd79 except 77:L)
|Binding:||The humanised mAb's affinity is 2-fold lower than that of the mouse by competition binding assays.|
|Expression:||Sp2/0 mouse myeloma cells|
|Comment:||Assays showed neutralising activity towards HSV-1.|
|José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.|